drugset / Trial / NCT00498836
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Sorafenib | Small molecule | 400 mg | — |